<br /> <b>Warning</b>: Undefined variable $td_logo_alt in <b>/home3/t5c1m0u4/public_html/new/wp-content/themes/infobioquimica/parts/header/header-style-1.php</b> on line <b>45</b><br />
www.infobioquimica.com
Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors Sponsors
Inicio Blog Página 35

#2016AACC PROTIA Allergy-Q detects up to 64 allergies in one panel

0

ProteomeTech is a biotech company developing immuno-diagnostic products and providing proteomics-based R&D services. They have accumulated proteomics-related technologies since 2000

ProteomeTech has several innovative IVD products; PROTIA Allergy-Q, allergy test detecting up to 64 allergies in one panel; ImmuneCheck IgG, Human IgG test adopting our own Q-Rapid Technology can get semi-quantitative results; DoubleCheck, pregnancy test with Q-Rapid Technology makes more accurate results possible.

Up to 64 detecting lines in one plate! Model:

  • PROTIA Allergy-Q Inhalant panel/Food panel/Atopy panel.
  • PROTIA Allergy-Q 64 Food panel/Inhalant panel.

Description:

  • Multiplex, semi-quantitative detection of allergen-specific IgE in human serum or plasma.
  • 44 or 60 allergens test in a single panel
  • Small sample volume: 50 μL
  • Time for a test run: approx. 2.5 hours
  • Internal calibration lines
  • Concordance with ImmunoCap: 96%
  • ISO13485, CE certificate
  • associated immunoblot devices: Q-Scan(manual), Q-Station(all automation)
  • PLA(Paralle Lines Array) Technology

This technology overcomes the hook effect by having two assay method lines (sandwich immunoassay line and competitive immunoassay line) in a single test.

It also makes quantitative detection possible for rapid kit. ProteomeTech owned, patent applied.

paneles

Web site: proteometech.com

Listado de emisiones anteriores

No se encontraron entradas.

#2016AACC Bio-Rad Takes Molecular Diagnostics Testing to a New Level

0

Bio-Rad unveils several new molecular quality controls, among which is the first molecular control to be issued a de novo clearance from the FDA. Join Max Williams, Global Marketing Director, Bio-Rad, Rochelle Stahl, Product Manager, Molecular Diagnostic Controls, Bio-Rad and Jamie Platt, PhD, CGMBS, MB(ASCP), President and Founder of BRIDGenomics to learn about how these new controls conveniently monitor the analytical process including sample extraction, amplification and detection. An exciting new video will be debuted highlighting Bio-Rad’s new offerings for molecular diagnostics testing. Light refreshments will be served.

Check out this Video: 

https://www.youtube.com/watch?v=RJ-BT1J1Gt8&amp;feature=youtu.be

#2016AACC Direct Mass Spectrometric Profiling of Biological Tissues

0

Prof. Zoltan Takats, PhD. Professor of Analytical Chemistry, Imperial College, London

Virginia LiVolsi, MD. University of Pennsylvania, Perelman School of Medicine

This lecture discusses the use of direct mass spectrometric profiling of biological tissues. One example is the “intelligent knife” technology, in which smoke collected during surgery performed using electrosurgical knives is Virginia Lavolsi analyzed by a mass spectrometer. This technology provides rapid diagnostic information to surgeons, such as during tumor resection.

Professor Zoltan Takats is a pioneer in the field of ambient mass spectrometry and its application to clinical specimens near the surgical suite. He is the primary inventor of six mass spectrometric ionization techniques. With the invention of the intelligent knife, mass spectrometry is now being brought directly to patients undergoing surgery. His laboratory continues to investigate the application of this technology to other important clinical questions, including those in the microbiology laboratory. Professor Takats  explores the clinical implications and future developments of this technology.

As part of the session, an experienced anatomic pathologist, Dr. Virginia LiVolsi from the Perelman School of Medicine at the University of Pennsylvania, gives her view of the technology and participate in the post-lecture Q&A.

Read the CLN Daily article: Going Under a Sharper Knife

Source: AACC

#2016AACC Practical Tools for taking change in laboratory automation

0

At the AACC annual Scientific Meeting, speakers laid out a plan for labs implementing new automation solutions, a complicated task with big implications for quality, efficiency and patient safet

Read the CLN Daily Article: Avoiding Eeny Meeny Miny Mo When Choosing Automation Solutions

#2016AACC The Epigenetic Basis of Common Human Disease

0

Dr. Andrew P. Feinberg, MD, MPH. Director of the Center for Epigenetics and King Fahd Professor of Medicine, Oncology, and Molecular Biology & Genetics, Johns Hopkins University School of Medicine

Dr. Feinberg will address important developments in epigenetics, a branch of science that studies the biochemical modifications of the genome. His early work included the discoveries of altered DNA methylation in human cancer, human imprinted genes and loss of imprinting (LOI) in cancer, and the molecular basis of Beckwith-Wiedemann syndrome and epigenetic risk of cancer. Most recently, he pioneered genome-scale epigenetics (epigenomics), with the first whole genome bisulfite sequencing analysis of human cancer, and the discovery of large hypomethylated blocks that correspond to nuclear lamina-associated heterochromatin, as well as a mechanism for disruption of these blocks in epithelial-mesenchymal transition. He has shown the close relationship between epigenomics changes in normal development, cancer, and stem cell reprogramming. These developments have exciting implications to molecular diagnostics and novel forms of therapy.

The Epigenetic Basis of Common Human Disease will take you on a journey into the biochemical modifications of the genome. Dr. Andrew Feinberg has made fundamental discoveries in the field, impacting diverse fields ranging from cancer, stem cells, molecular diagnostics, and novel therapeutics.

Read the CLN Daily article: More than DNA Sequence: Epigenetics in Human Disease

Source: AACC

#2016AACC Siemens Healthineers Unveils Game-changing Atellica Solution

0
  • Patented, bi-directional magnetic sample transport technology1 is 10 times faster than conventional conveyors
  • Immunoassay analyzer delivers the industry’s highest productivity per square meter2—more than 400 tests per hour3
  • Multi-camera vision system and intelligent sample routing enable independent control over every sample from routine to STATs1
  • Scalable up to 10 components and more than 300 customizable configurations1 can be used as a standalone system or connected to automation1
  • Can handle more than 30 sample container types including pediatric and special containers

Today Siemens Healthineers unveiled the Atellica™ Solution,1 a highly flexible immunoassay and clinical chemistry solution featuring patented bi-directional magnetic sample-transport technology that is 10 times faster than conventional conveyors.1 The unveiling occurred during the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, July 31 – August 4 (booth 2101).

“We engineered the Atellica Solution1 based on our customers’ needs and extensive research of market trends,” said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers. “The result is a game-changer that delivers control and simplicity, so our customers can focus on driving better business and clinical outcomes and spend less time managing operations.”                                                

In addition to the speed afforded by the Atellica Magline™ Transport technology,1 the Atellica Solution1 offers a multi-camera vision system1 and intelligent sample routing1 for independent control over every sample from routines to STATs.

The Atellica Solution1 provides unprecedented flexibility to adapt to growing testing needs and space constraints. The solution can be used as a stand-alone system, is scalable up to 10 components and can be combined into more than 300 customizable configurations,1 including L-shaped, U-shaped, and linear formations. It can also be connected to Aptio® Automation for a comprehensive multidisciplinary solution.1 The solution can handle more than 30 sample container types including pediatric and special containers.

Further, the same reagents can be used across configurations and locations, simplifying laboratory operations, streamlining inventory control, and enabling consistent testing results. Additionally, a single immunoassay analyzer processes more than 400 tests per hour,3 delivering the highest productivity per square meter in the industry.2

Other benefits of the Atellica Solution1 include remote-access monitoring and control1 to maximize uptime, and a broad, expanding assay menu1 using proven detection technologies.

The Atellica Solution1 is the first in a new line of Atellica products engineered by Siemens Healthineers and further innovations are in the R&D pipeline.

  1. Products are under FDA review.  Not available for sale.  Any features listed are part of the development design goals.  Future availability cannot be guaranteed.
  2. Versus leading IVD market competitors.
  3. Dependent upon test mix.

 

For further information on Siemens Healthineers, please see www.healthcare.siemens.com.

For further information on the Atellica Solution and other Siemens Healthineers products being exhibited at AACC, please see www.siemens.com/aacc.

#2016AACC Theranos Science & Technology: The Miniaturization of Laboratory Testing

0

Theranos CEO Elizabeth Holmes presented a special session about her proprietary technology.

Theranos was founded in 2003 by Elizabeth Holmes with the goal of streamlining and standardizing blood tests by creating a hand-held device.

Theranos Web site: www.theranos.com

#2016AACC Plenary session: Halving Premature Death

0

Sir Richard Peto is an epidemiologist of world stature who has made important contributions to meta-analysis and who has led a number of practice-changing clinical trials.

Sir Richard Peto gave an overview of the important causes of death in different parts of the world, highlighting the effects of preventable causes of death, such as tobacco and alcohol. He and his colleagues have been responsible for demonstrating the current and the future size of the growing worldwide epidemic of death from tobacco and for establishing a worldwide network of large prospective and retrospective studies to monitor the growth of this epidemic over the next few decades. Sir Richard will explain his vision that with global efforts, halving premature death should be an achievable goal.

Read the CLN Daily Article: A Bold Vision for Reducing Premature Death

Source: AACC

#2016AACC First Plenary: Bio-Nano-Chip technology

0

First plenary of ‪#‎2016AACC‬ is about programmable bio-nano-chip technology. Dr. McDevitt has pioneered this technology for digitizing biological signatures for a broad range of key health conditions, with numerous applications.

Source: AACC

1...343536...60Página 35 de 60

Agenda

       

Radio El Microscopio

Ze Xiong

Últimas notas publicadas

INFOBIOQUIMICA.ORG